

Supplementary Materials

Table S1. Number of patients per group receiving each antibiotic partner according to route of administration.

	Group 1	Group 2
<u>Intravenous</u>		
Vancomycin	15	28
Flucloxacillin	9	8
Clindamycin	7	3
Ceftriaxon	4	6
Sultamicillin	2	4
Ampicillin	2	0
Meropenem	2	7
Fucidic acid	2	2
Penicillin	1	1
Cefuroxim	1	0
Ciprofloxacin	1	1
Levofloxacin	1	1
Fosfomycin	1	1
Amoxicillin	1	0
Piperacillin/Tazobactam	1	0
Teicoplanin	0	4
Daptomycin	0	5
Cephazolin	0	1
Cefotaxim	0	1
Ceftazidim	0	1
<u>Oral</u>		
Linezolid	13	28
Clindamycin	6	4
Amoxicillin/Clavulanate	5	0
Penicillin	3	0
Cefuroxim	2	2
Fucidic acid	2	2
Fosfomycin	1	1
Cefotaxim	1	0
Ciprofloxacin	0	5
Doxycyclin	0	1
Flucloxacillin	0	4

Table S2. Number of patients per group and per detected pathogens.

	Group 1	Rifampin MIC (µg/ml)	Group 2	Rifampin MIC (µg/ml)
<i>Staphylococcus epidermidis</i>	10	≤ 0.5	19	≤ 0.5
<i>Enterococcus faecalis</i>	6	≤ 0.5	7	≤ 0.5
<i>Staphylococcus aureus</i>	6	≤ 0.5	9	≤ 0.5
<i>Staphylococcus haemolyticus</i>	5	≤ 0.5	7	≤ 0.5
<i>Staphylococcus capitis</i>	3	≤ 0.5	4	≤ 0.5
<i>Enterococcus faecium</i>	3	≤ 0.5	1	≤ 0.5
<i>Staphylococcus hominis</i>	2	≤ 0.5	2	≤ 0.5
<i>Pseudomonas aeruginosa</i>	2	x	1	x
<i>Proteus mirabilis</i>	2	x	2	x
<i>Staphylococcus pettenkoferi</i>	1	≤ 0.5	1	≤ 0.5
<i>Klebsiella aerogenes</i>	1	x	0	x
<i>Klebsiella pneumoniae</i>	1	x	5	x
<i>Escherichia coli</i>	1	x	2	x
<i>Staphylococcus lugdunensis</i>	1	≤ 0.5	0	x
<i>Streptococcus dysgalactiae</i>	1	x	0	x
<i>Moraxella bovis</i>	1	≤ 0.5	0	x
<i>Staphylococcus cohnii</i>	1	≤ 0.5	1	≤ 0.5
<i>Cutibacterium acnes</i>	1	≤ 0.5	1	≤ 0.5
<i>Enterobacter cloacae</i>	0	x	3	x
<i>Acinetobacter lwoffii</i>	0	x	1	x
<i>Streptococcus agalactiae</i>	0	x	1	x
<u>Rifampin resistant</u>				
<i>Staphylococcus epidermidis</i>	10	≥ 32	31	≥ 32
<i>Staphylococcus epidermidis</i>	1	≥ 16	3	≥ 16
<i>Staphylococcus haemolyticus</i>	2	≥ 32	2	≥ 32
<i>Staphylococcus hominis</i>	1	8	1	2
<i>Staphylococcus capitis</i>	0	x	1	≥ 32

* MIC Minimum Inhibitory Concentration